Shan Lu, PhD

Doctoral Degree: University of Texas 1995 (Biomedical Sciences)

Master's Degree: University of Texas Graduate School of Biomedical Sciences 1993 (Molecular Biology)

Bachelor's Degree: Bejing Normal University 1988 (Biology)

Post Doctoral Fellowship: Baylor College of Medicine 1998 (Molecular Endocrinology )

Prostate and Breast, Molecular Endocrinology, Integrative Biology and Pharmacology, Molecular and Cellular Biology, Hematology Oncology 
 

- Associate Professor, Department of Pathology and Laboratory Medicine, Cardiovascular Center - CVC

Investigators:Lu, Shan 01-01-2006 -12-31-2006 American Cancer Society - Ohio Chapter Vav3 in Prostate Cancer Role:PI Closed 001835-001 Level:Private Non-Profit

Grant: #uc Investigators:Lu, Shan 07-01-2006 -06-30-2008 Ohio Cancer Research Associates The Molecular Pathway of Vav3-Mediated Androgen Receptor Activation in Prostate Cancer Role:PI Closed 001893-001 Level:Private Non-Profit

Grant: #R01 CA119935 Investigators:Lu, Shan 08-28-2007 -05-31-2012 National Cancer Institute Vav3 Oncogene in Prostate Cancer Role:PI Active 005170-001 Level:Federal

Grant: #R21CA223049 Investigators:Dong, Zhongyun; Lu, Shan 08-01-2018 -07-31-2020 National Cancer Institute Preclinical safety and efficacy assessment of a novel PCNA inhibitor for prostate cancer therapy Role:Collaborator $208,854.00 Active Level:Federal

Grant: #W81XWH-22-1-0815 Investigators:Dong, Zhongyun; Lu, Shan 09-30-2022 -09-29-2025 Department of the Army Medical Research Acquisition Activity Targeting proliferating cell nuclear antigen for enhancing efficacy of radiotherapy in prostate cancer Role:Collaborator 1164481.00 Active Level:Federal

Peer Reviewed Publications

Liu,Y., Mo,J.Q., Hu,Q., Boivin,G., Levin,L., Lu.S., Yang,D., Dong,Z.Y., and Lu,S  (2008). Targeted overexpression of Vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Research, 68, 6396-6406

Lee,K, Liu,Y., Mo,J.Q., Zhang,J., Dong, Z.Y., Lu, S  (2008). Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BCM cancer, 8, 158

Lu, S., Wang, A., Lu, S., and Dong, Z.Y  (2007). DL3 is a novel anti-androgen and interrupts androgen receptor signaling in prostate cancer cells. Mol. Cancer Ther, 6 (7) , 2057-2064

Lu,S., Lee,J., Revelo,M., Wang,X., Lu,S., and Dong,Z.Y  (2007). Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clinical Cancer Research, 13 (19) , 5692-702

Dong,Z.Y., Liu,Y., Lee,K., Lu,S., Wang, A., Wang,L.H., Revelo,M., and Lu,S  (2006). Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol. Endo., 20, 2315-2325

Lu,S., Tan,Z., Wortaman,M., Lu,S., and Dong,Z.Y.  (2010). Androgen receptor-dependent regulation of heat shock protein 70 in human prostate cancer cells. Int J Oncol., 36, 459-467

Liu,Y., Wu,X., Dong,Z.Y., and Lu,S.  (2010). The molecular mechanisms of Vav3 oncogene activation of androgen receptor in human prostate cancer cells. Int J Oncol., 36, 623-633

Lu, S., Tan,Z., Wortman,M., Lu,S., and Dong,Z.U.  (2010). Preferential Induction of G1 Arrest in Androgen Responsive Human Prostate Cancer Cells by Androgen Receptor Signaling Antagonists DL3 and antiandrogen bicalutamide. Cancer Letters, 298, 250-7

Dong,Z.Y., Liu,Y., Levin,L., Scott,K., Gaitonde,K., Wang,J., Zhai,Q., Oleksowicz,L., and Lu, S.  (2010). Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis, 31, 1948-1955

Dong,Z.Y., Liu,Y., Levin,L., Oleksowicz,L., Wang,J., and Lu, S.  (2011). Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer. Oncology Reports, 25 (6) , 1511-6

Academic - Cardiovascular Diseases Center
231 Albert Sabin Way
Cincinnati  Ohio, 45267
Phone: 513-558-5109
Fax: 513-558-2289
shan.lu@uc.edu